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1. Introduction 
 
The introduction of this cumulative habilitation thesis will provide a background of the nature 
and prognosis of aortic valve stenosis. Treatment options of aortic stenosis will be discussed 
and the development of transcatheter aortic valve implantation (TAVI) will be reviewed. 
Furthermore, previous research is summarized and a list of open questions and areas of 
research are provided.  
1.1. Aortic stenosis 
 
Aortic stenosis occurs due to calcific degeneration of a tricuspid or bicuspid valve, or due to 
rheumatic heart disease. Calcific aortic stenosis is the most frequent cause of valvular heart 
disease in the Western world, and the leading indication for operative valve replacement. The 
prevalence of aortic stenosis increases with age and reaches almost 5% in patients ≥ 75 years 
(Figure 1)
1
. Aortic stenosis is a mechanical problem that requires a mechanical solution. If 
treated with medical therapy only, patients experience a high rate of death
2, 3
.  
 
Figure 1. A severely calcified and stenotic aortic valve (left). The prevalence of moderate or severe aortic stenosis 
increases with age (right). 
 
Surgical aortic valve replacement improves both symptoms and survival in patients with 
severe stenosis; but with advanced age, poor left ventricular function, or comorbidities, 
operative risk may be high or even prohibitive
4, 5
. A survey of European hospitals in 2001 
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found that surgery was not offered in 10% of patients with severe aortic stenosis
6
. In addition, 
many elderly patients refuse to undergo open heart surgery. As aconsequence, during the last 
decade, transcatheter aortic valve implantation (TAVI) has emerged as an alternative, less 
invasive treatment option in such patients
7, 8
. 
1.2. A brief history of TAVI 
 
The search for less invasive treatment options for patients with valvular heart disease was 
pioneered by Hywel Davies in 1965. Davies developed a parachute-like valve to treat aortic 
regurgitation. The valve was placed in the descending aorta and offered little resistance to the 
systolic blood flow in antegrade direction, but passively opened during diastole to obstruct the 
retrograde diastolic flow
9
. However, such valves were never utilized in humans.  
 
Figure 2. In 1965, Hywel Davies implanted a parachute-like valve in the descending aorta of a dog. The valve was 
intended to treat patients with aortic regurgitation but was never utilized in humans. 
 
In 1985, Alain Cribier performed the first aortic balloon valvuloplasty, which was the first 
catheter-based intervention specifically designed to treat non-operable calcific aortic 
stenosis
10
. At that time, age > 75 years per se was often a contraindication to aortic valve 
replacement. After rapid adoption of balloon valvuloplasty and explosive growth worldwide, 
the lack of survival benefit and the high recurrence rate of severe stenosis led to a marked 
decline in its use
11
.  
In 1989, Henning Andersen developed a balloon expandable aortic valve that could be 
implanted percutaneously in a porcine model
12
, but he did never use this technique in humans. 
The first in human transcatheter valve implantation was performed by Philip Bonhoeffer in 
2000. He implanted a stented valve made of a bovine jugular vein into a pulmonary artery 
conduit of a young patient with congenital heart disease. 
5 
 
 
Figure 3. In 1985, the first balloon aortic valvuloplasty was performed by Alain Cribier in Rouen, France (A). Four years 
later, Henning-Rud Andersen implanted a balloon expandable valve within a porcine model (B). The first in man 
transcatheter valve implantation was performed 2000 by Philip Bonhoeffer in Paris utilizing a valve made of a bovine 
jugular vein (C). 
 
Soon after the development of aortic balloon valvuloplasty, Alain Cribier started working on a 
stent that could deploy an aortic valve in patients with calcific stenosis, regardless of the 
amount of calcification
11
. It took 9 years of development and animal trials until the first-in-
man implantation of a transcatheter aortic valve could be successfully performed on April 16
th
, 
2002 by Alain Cribier in Rouen, France. Cribier implanted a 23 mm balloon-expandable 
transcatheter heart valve in a patient with severe heart failure and multiple comorbidities 
utilizing an antegrade transseptal approach through the femoral vein.  
The retrograde transfemoral arterial access with a balloon expandable valve was later 
developed and standardized in Vancouver by John Webb in 2005
13
. This approach allowed a 
higher technical success rate, although there was an initial learning curve with a relatively 
high rates of vascular complications. At the same time, Eberhard Grube and Jean-Claude 
Labordé started implanting a self-expanding valve with porcine pericardial tissue leaflet, the 
CoreValve
14
. 
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Figure 4. Alain Cribier developed a balloon expandable bovine valve on a cobalt chromium alloy stent (A). The first-in-
man transcatheter aortic valve implantation was performed in 2002 utilizing an antegrade transvenous approach (B).  
 
With the initial high profile catheters and sheaths, not all patients could be treated through the 
femoral arteries. In 2006, Sam Lichtenstein, a cardiac surgeon from Vancouver, performed 
the first transapical TAVI through a left-sided mini thoracotomy. During the following years, 
other alternative access routes were developed including the transaxillary/subclavian access, 
the direct aortic access, and even a transcarotid access. In Switzerland, the first TAVI was 
performed in 2007. It is estimated that as of 2012, about 100’000 TAVI procedures have been 
performed worldwide. 
 
Figure 5. Pioneers in transcatheter aortic valve implantation. From left to right: Alain Cribier, John Webb, and Eberhard 
Grube. 
 
7 
 
1.3. Summary of previous research 
 
After Cribier et al. had reported the short-term outcome of their first 6 patients in 2004 
utilizing the antegrade transvenous approach
15
, Webb et al. and others reported their 
experience with the retrograde transarterial access
13, 14, 16-21
. From these early transarterial case 
series, it became evident that vascular complications were one of the limiting factors of 
transarterial transfemoral TAVI. These complications included dissection or rupture of the 
iliac and femoral arteries, the aorta, and the aortic annulus and were reported in up to 30% of 
patients undergoing TAVI with the early high profile catheters requiring 22-24 F sheaths. In 
an attempt to reduce iliofemoral complications, a surgical cut-down to expose and control the 
iliofemoral artery above and below the puncture site was initially performed 
8, 13, 14, 16, 21-23
. 
Later, operators started utilizing percutaneous closure devices to reduce the invasiveness of 
the procedure and allow earlier patient ambulation
18-20, 24-26
.  
Another problem that was recognized very early were paravalvular leaks. Cribier noted in his 
first publication that 2/6 patients had severe paravalvular aortic regurgitation (PAR) following 
TAVI
15
. Subsequent publications reported moderate or severe PAR in 8-22%. Patients with 
acute severe PAR often developed cardiogenic shock, but the relevance of moderate or mild 
PAR was less clear. It was known that there were different mechanisms that caused PAR. 
Undersizing of transcatheter valves was the most frequent cause, but malpositioning (too low 
or too high), or severe calcification were other causes. Before 2010, valves were selected 
based on a single measurement of the annular diameter on transthoracic or transesophageal 
echocardiography
27
. However, the annulus is a complex, three-dimensional, nearly uniformly 
oval shaped structure
28
. To measure the annulus in its true plane, a three-dimensional imaging 
modality appeared necessary, but it was unknown if such a strategy will truly lead to less PAR. 
Furthermore, there was a concern that larger valves may increase the risk for annular rupture.  
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Figure 6. Mechanisms of paravalvular regurgitation. Heavily calcified leaflets may prevent complete sealing (A, arrow). 
The potential hazards hazards of 2-dimensional imaging techniques for measurements of a 3-dimensional, oval structure 
is demonstrated in B. The true annular diameter is underestimated in both measurements (arrow 1, tangential 
measurement, arrow 2, measurement of the short axis). C shows a correctly positioned CoreValve. Paravalvular 
regurgitation (red arrows) may result from too low (D) or too high (E) implantation. 
 
Initially, the rate of cerebrovascular events during and after TAVI ranged between 2-6%, 
although definitions did vary
13, 16, 18-21, 29, 30
. However, it was the publication of the PARTNER 
A trial that made the risk for strokes one of the hot research topics in TAVI
7
. In this trial, the 
rate of cerebrovascular events (including major strokes, minor strokes, and transient ischemic 
attacks) was higher in the TAVI group than in the surgical group, although the rates of strokes 
(4.6% vs. 2.4% at 30 days) did not differ significantly. Periprocedural strokes may result from 
embolization of calcified microdebris during positioning and deployment of the valve, but 
also during passage through the aortic arch with the guidewire and the catheter, during 
balloon valvuloplasty, or re-capture of a valve . Not infrequently, strokes occurred during the 
first 1-2 days after the procedure. These postprocedural stroke may be due to the non-
endothelialised and thrombogenic bioprosthesis itself, new-onset atrial fibrillation, late 
calcific embolism, or possibly due to late thrombosis or hemorrhage following earlier 
embolism. 
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1.4. Unsolved issues and open questions 
 
After the pioneering initial use of TAVI proofing its feasibility, several open questions 
remained: 
 Patient selection 
 Vascular complications 
 Valve sizing and paravalvular regurgitation 
 Cerebrovascular events 
 Need for a permanent pacemaker 
 Safety and efficacy of next-generation valves 
 Long-term outcome and valve durability 
 
 
Figure 7. Currently, the two most frequently implanted valves include the Edwards SAPIEN XT (Edwards Lifesciences, 
Irvine, USA) and the Medtronic CoreValve (Medtronic Inc., Minneapolis, USA).  
 
The research presented and discussed in this cumulative habilitation thesis aims to answer 
some of these open questions. The research addressing such issues was performed at St. 
Paul’s Hospital, University of British Columbia, Vancouver, Canada. Some of the projects 
were done in collaboration with other centers such as the Québec Heart and Lung Institute, 
Québec City, Canada, the Cleveland Clinic, Cleveland, USA, and Aarhus University Hospital, 
Aarhus, Denmark. 
10 
 
First, the relevance of concomitant mitral regurgitation in patients with severe aortic stenosis 
undergoing TAVI was investigated (Toggweiler et al., J Am Coll Cardiol 2012). We showed 
that women may be excellent candidates for TAVI (Humphries, Toggweiler et al., J Am Coll 
Cardiol 2012). Then, the role of  annular measurements with computed tomography for valve 
sizing protocols and their impact on the reduction of paravalvular regurgitation after TAVI 
was investigated (Willson et al., J Am Coll Cardiol 2012). Predictors for vascular 
complications, initially the most feared complication in TAVI, were then identified and their 
importance for patient selection and complication rates defined (Toggweiler et al., J Am Coll 
Cardiol 2012). Finally, five year outcome of TAVI was for the first time evaluated 
(Toggweiler et al., J Am Coll Cardiol 2012). 
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2. Patient selection: TAVI in specific patient subgroups 
 
Typically, patients that are currently selected for TAVI are more than 80 years old, and have 
comorbidities such as coronary artery disease, diabetes, a prior stroke, chronic pulmonary 
disease, or kidney disease. These restrictions are applied more rigidly in North America than 
in other part of the world. Across Europe and especially in Germany, there is a trend towards 
TAVI in lower (intermediate) risk patients. Multicenter trials randomizing such patients vs. 
open heart surgery are under way (PARTNER 2, ADVANCE). With the current high-risk 
patients, studies with follow-ups beyond 2 years have shown that the median time of survival 
after TAVI is about 3 years
31
. Subgroup analyses of the PARTNER trial have demonstrated 
that long-term survival is mainly determined by (non-cardiac) comorbidities
32
. Therefore, 
TAVI should not be performed in the presence of relevant comorbidities that limit survival to 
less than 2-3 years. It is now generally recommended that each patient should be discussed 
and selected by a multidisciplinary Heart Team including cardiologists and cardiac surgeons. 
However, there are certain subgroups of patients that may benefit more from TAVI than 
others. Two of these subgroups may be patients with concomitant mitral regurgitation and 
women. 
2.1. TAVI in patients with concomitant mitral regurgitation 
 
Concomitant mitral regurgitation (MR) is present in most patients with severe aortic stenosis. 
The reported prevalence of moderate or severe MR in patients undergoing surgical aortic 
valve replacement ranges from 13% to 75%. Traditionally, patients with severe aortic stenosis 
and concomitant severe MR have been treated with surgical aortic valve replacement and 
mitral valve reconstruction or replacement. Patients with severe aortic stenosis and 
concomitant mild or less MR have been treated with aortic valve replacement only. The 
situation is less clear in patients with severe aortic stenosis and moderate MR. In contrast to 
surgical aortic valve replacement concurrent mitral valve repair or replacement has not been 
an option in patients undergoing TAVI, although new transcatheter mitral therapies such as 
the Mitraclip (Abbott Vascular, Illionois, USA) may offer options in future
33
.  
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To better define the role of MR for outcome after TAVI, we tried to address the following 
clinical questions: 
 What is the impact of MR on outcome after TAVI? 
 Does MR improve after TAVI? 
 Are there certain factors that predict improvement? 
 
A total of 451 patients undergoing TAVI with a balloon expandable valve (Cribier Edwards, 
Edwards SAPIEN, and Edwards SAPIEN XT, all Edwards Lifesciences, Irvine, USA) at St. 
Paul’s Hospital, Vancouver, British Columbia, and at the Quebec Heart and Lung Institute, 
Quebec City were analyzed
34
. MR at baseline was ≤ mild in 319 patients (71%), moderate in 
89 (20%) and severe in 43 (10%). Patients with moderate or severe MR were older, were 
more often in atrial fibrillation, had more often a prior myocardial infarction, a lower ejection 
fraction, a smaller aortic valve area, and a higher Society of Thoracic Surgeons’ (STS) risk 
score.  
 
Figure 8. Kaplan-Meier curves for all-cause mortality in patients with none, trivial or mild MR and moderate or severe 
MR at baseline. (Toggweiler et al., J Am Coll Cardiol 2012;59:2068-2074) 
Compared to patients with none, trivial or mild MR, patients with moderate/severe MR had a 
higher mortality rate during the first 30 days (unadjusted hazard ratio (HR) 2.04,  95% 
confidence interval (CI) 1.11 – 3.74, p = 0.02; adjusted HR 2.10, 95% CI 1.12 – 3.94, p = 
0.02) but no difference after 30 days (unadjusted HR 0.94, 0.58 – 1.51, p = 0.80; adjusted HR 
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0.82, 0.50 – 1.34, p = 0.42). Therefore, moderate or severe MR was associated with an 
increased early, but not late mortality. 
Since the severity of MR depends primarily on regurgitant orifice area and the systolic 
pressure gradient between the left ventricle and the left atrium, MR is expected to improve 
immediately after TAVI and may improve further in the mid- and long-term should positive 
left ventricular remodeling occur
35, 36
. Indeed, in our study, we observed that a few days after 
TAVI, MR improved in 61% of the patients with moderate or severe MR at baseline, and 
rarely worsened. At 1 year follow-up MR had improved in 55%, remained unchanged in 16%, 
and worsened in 1%; the remaining 28% had died.  
 
Figure 9. The degree of mitral regurgitation (MR) post TAVI and at 1 year follow-up in patients with moderate or severe 
mitral regurgitation at baseline. (Toggweiler et al., J Am Coll Cardiol 2012;59:2068-2074) 
 
As expected, multivariable predictors of improved MR at 1 year (vs. unchanged MR, worse 
MR or death) were a mean aortic transvalvular gradient ≥ 40 mmHg, functional (as opposed 
to structural) MR, the absence of pulmonary hypertension, and the absence of atrial 
fibrillation. Indeed, a higher mean aortic transvalvular gradient at baseline results in a greater 
drop in afterload after TAVI and therefore also in a greater reduction of MR. In case of a 
positive left ventricular remodeling, patients with functional MR may improve even more. 
Pulmonary hypertension has been identified as a predictor of mortality and adverse outcome 
in previous studies. Finally, atrial fibrillation may worsen MR due to atrial and annular 
enlargement.  
14 
 
The randomized Placement of Aortic Transcatheter Valves (PARTNER) study suggested that 
patients with moderate or severe mitral regurgitation may derive a larger benefit from TAVI 
compared to both medical management and surgical aortic valve replacement
7, 8
. In the 
PARTNER B study, subgroup analysis showed that the number needed to treat to prevent 1 
death at 1 year was 3 in patients with moderate or severe MR versus 7 in patients without it. 
In the PARTNER A study, 1-year mortality of patients with moderate or severe MR was 
24.2% after TAVI (similar to the 27.7% in our study) and as high as 35% after surgical aortic 
valve replacement. 
In conclusion, patients with severe aortic stenosis and concomitant moderate or severe MR 
have a very poor prognosis, if treated with medical therapy. Procedural mortality is increased 
in patients with advanced MR. Nevertheless these findings demonstrate late functional benefit 
in survivors and are consistent with (but do not prove) a possible late survival benefit. MR 
improved in over one half of patients at 1-year follow-up due to the combination of a reduced 
afterload and a positive remodeling. Improvement was more likely in patients with a high 
aortic transvalular gradient, functional MR, without pulmonary hypertension and without 
atrial fibrillation. Thus, such patients with severe aortic stenosis and concomitant moderate or 
severe MR may be ideal candidates for isolated treatment of aortic valve disease. 
2.2. TAVI in women 
 
In the PARTNER trial, a pre-specified subgroup analysis suggested that women benefit more 
from TAVI than men do
7
. Two additional publications examined sex differences in outcomes 
after TAVI. One found no difference in mortality at 30 days and 1 year after TAVI
37
. One 
study analyzing 260 consecutive patients reported better 1-year survival in women, but failed 
to adjust for baseline characteristics, which varied substantially between men and women
38
.  
In light of limited and conflicting evidence, we aimed to answer the following questions: 
 Are there difference in baseline characterics between men and women? 
 Does periprocedural outcome differ between men and women? 
 Is there a difference in long-term survival? 
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We evaluated 641 consecutive patients (51% women, 49% men) who underwent TAVI at St. 
Paul’s Hospital, Vancouver, Canada, and at the Québec Heart and Lung Institute, Québec City, 
Canada
39
. 
We found that women had higher mean aortic gradients, worse renal function, more often a 
porcelain aorta, and a better left-ventricular systolic function than men. Women were more 
often frail, while coronary artery disease, a prior myocardial infarction, prior percutaneous 
revascularisazion and chronic obstructive pulmonary disease (COPD) was more frequently 
present in men. 
We made the following observations regarding procedural outcome: 
 Women had more vascular complications 
 Women had more life-threatening bleeds 
 Women required more blood transfusions 
 Despite these adverse events, the (adjusted) female odds ratio for 30-day mortality 
was 0.39 (95% CI 0.19 – 0.80) 
This 30 day survival advantage was maintained up to 2 years: 
 
Figure 10. Women’s survival advantage after TAVI throughout the 2-year follow-up period. (Humphries et al., J Am Coll 
Cardiol 2012;60:882-886.) 
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The reason for these findings remains unclear. It is unlikely that the survival advantage can be 
explained by the difference in baseline characteristics such as coronary artery disease. Also, 
the higher post-procedural complication rate may increase short- and mid-term mortality. One 
possible explanation may be the fact that interstitial fibrosis is more pronounced in male 
hearts with severe aortic stenosis, as is collagen I, II, and matrix metalloproteinase 
expression
40, 41
. Lower levels of fibrosis in women might lead to more rapid reversal of 
myocardial hypertrophy after correction of aortic stenosis
42
. Another explanation for the 
survival advantage might be the higher life-expectancy of women. However, the Kaplan 
Meier figure shows that the curves separate during the first 6 months and are parallel 
thereafter. The reason for this early survival advantage despite the higher periprocedural 
complication rate remained unclear. 
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3. Measurement of the aortic annulus and valve sizing 
 
While during open heart surgery the aortic annulus can be directly inspected and sized, TAVI 
operators depend on external, indirect measurements of annular size. However, correct sizing 
of the annulus and choice of prosthesis is of utmost importance in order to avoid paravalvular 
leakage, device embolization, and annular rupture. Studies have shown that about 10-20% of 
patients are left with moderate or severe paravalvular regurgitation after TAVI and this has 
been associated with increased morbidity and mortality in several independent publications
43-
45
. 
During the early experience with TAVI, the annulus was measured with 2-dimensional 
echocardiography using the parasternal long-axis view durig transthoracic echocardiography 
(TTE)  or with transesophageal echocardiography (TEE)  in the ~130° view. However, it is 
well known that the annulus is an oval structure where the long axis is in average 5-6 mm 
(about 20%) longer than the short axis
46, 47
. Therefore, measuring an oval-shaped annulus in 
only one dimension may under- or overestimate it’s true size.  
On the other hand, multidetector computed tomography (MDCT) offers a 3-dimensional to 
echocardiography and allows reconstruction of the aortic annulus in it’s true plane. Utilizing 
MDCT for annulus measurements, we aimed to address the following questions: 
 Does valve sizing according to MDCT annular measurements result in lower rates 
of paravalvular regurgitation? 
  How should MDCT be integrated into valve sizing protocols? 
 
 
Figure 11. In a 82 year old patient, a 23-mm Sapien XT (Edwards Lifesciences, Irvine, California) valve was selected based 
on a TEE annular diameter of 22 mm (A). The MDCT mean annular diameter was 25 mm (22 x 28 mm) and area 4.90 cm2. 
The THV was undersized by 2 mm relative to the mean diameter and by 15% relative to the annular area (B). The THV 
appeared undersized on aortic root angiography (C). The patient had moderate to severe paravalvular regurgitation on 
echocardiography (D). 
18 
 
3.1. MDCT based annular measurements 
 
We analyzed a total of 109 consecutive patients who underwent MDCT before TAVI at 2 
centers, St. Paul’s Hospital, Vancouver, Canada and Aarhus University Hospital, Aarhus, 
Denmark. Annular size was measured by TEE and MDCT. Valve size was chosen based on 
TEE measurements. A subset of patients (n = 50) also underwent MDCT before discharge to 
assess post-implant geometry of the balloon-expandable valves
47
. 
In our study, there was no patient with annular rupture, although this has been a concern when 
oversizing balloon expandable valves. The mean  MDCT mean annular diameter was 23.9 ± 
2.4 mm which was significantly larger than the mean TEE annular diameter (22.5 ± 1.9 mm, p 
< 0.01).  
 
Figure 12. In a 79 year old patient TEE measured an annulus of 2.1 cm suggesting a 23 mm Edwards SAPIEN or a 26 mm 
Medtronic CoreValve (A). CT angiography measured an area of 481 mm2 (C) and a mean diameter of 24 mm (B) 
suggesting a 26 mm Edwards SAPIEN or a 29 mm Medtronic CoreValve valve with ~10% oversizing. A 26 mm Edwards 
SAPIEN valve was implanted with trace paravalvular leak (D). 
 
Undersizing the nominal diameter or area of the valve relative to the MDCT measurements 
resulted in significantly more moderate or even severe paravalvular regurgitation. MDCT 
diameter (area under the curve (AUC)  0.81) and area (AUC 0.80) were more predictive of 
moderate or severe paravalvular regurgitation than TEE annulus diameter (AUC 0.70). For 
19 
 
patients with a valve diameter – mean annulus diameter < 1 mm, the incidence of moderate or 
severe paravalvular regurgitation was 21.4% vs 2.2% when the difference was  ≥ 1 mm. For 
patients with a nominal area < 10% greater than the annular area, the incidence of moderate or 
severe paravalvular regurgitation was 19.1% vs. 0% when the nominal area was > 10% above 
the annular area.  
Our results indicate that CT annular measurements have a good predictive value of moderate 
or severe paravalvular regurgitation following TAVI. Two-dimensional TEE measurements 
did often underestimate the true annular size. Our results therefore suggest that when utilizing 
CT measurements for valve sizing, the valve should be oversized by 10% relative to the 
measured area and by 1 mm  relative to the mean diameter. 
Based on these results, we published sizing recommendations for balloon expandable valves 
with the goal to oversize the valve relative to the measured area by 10-15%
48
. 
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4. Predictors and relevance of vascular complications 
 
Vascular complications are a major limiting factor when utilizing the large sheaths and 
catheters required for TAVI. For example, the rigorously monitored randomized PARTNER 
1B trial that used the large 22- and 24 F sheaths reported major vascular complications in 
30.7% of patients. Depending on its severity, vascular complications are associated with 
relevant mortality and morbidity
49
. Most studies have used non-standardized definitions and 
thus have yielded a wide range of vascular complication rates. In an attempt to allow direct 
comparison between clinical trials, the Valve Academic Research Consortium (VARC) has 
proposed standardized definitions for clinical endpoints
50, 51
 which have recently been 
revised
52, 53
.  
Based on these data, we aimed to address the following issues with our research project: 
 Evaluate the frequency and type of vascular complications in patients undergoing 
TAVI using current techniques and equipment 
 Identify predictors for vascular complications 
 
In this single-center study, we analyzed 137 patients undergoing percutaneous transfemoral 
TAVI at St. Paul’s Hospital, Vancouver, British Columbia. All patients were evaluated with 
fluoroscopy and most also with CT angiography. Vascular and bleeding complications were 
defined according to the VARC and occurred in 24 patients (18%), major vascular 
complications in 5 (4%). We identified 3 predictors for vascular complications:  
 Sheath size > minimal arterial diameter (as assessed by fluoroscopy and CT 
angiography) 
 Moderate or severe calcification of the iliofemoral arteries as assessed by CT 
angiography 
 Operator’s experience 
The rate of vascular complications was higher when the minimal artery diameter was smaller 
than the external sheath diameter (24% vs. 10%, p = 0.03), in the presence of moderate or 
severe calcification (29% vs. 9%, p = 0.03). The rate of vascular complications fell from 32% 
to 9% during the study period indicating a learning curve. We also showed that major 
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vascular complications were associated with a 30 day mortality rate of 20% and that the 
duration of hospital stay was more than twice as long as without complications. 
Transfemoral access is considered the access of choice due to its least invasive nature and is 
feasible in the majority of patients undergoing TAVI. Most interventional cardiologists are 
very familiar with the transfemoral route due to their experience with percutaneous coronary 
intervention. However, iliofemoral complications are the most common vascular 
complications in transfemoral TAVI. These complications include iliofemoral dissection, 
iliofemoral rupture, access site infection, stenosis, thrombosis, or occlusion, pseudoaneurysms, 
and femoral bleeding. To avoid these complications, a surgical cut-down was often performed 
in initial studies. A planned surgical cut-down can be performed at the beginning of the 
procedure to allow visualization and selection of the ideal puncture site and control of the 
artery above and below the puncture. Alternatively, a percutaneous puncture is performed and 
the artery is exposed for closure only. More recently, operators utilized percutaneous closure 
devices. Our study showed that with a fully percutaneous procedure utilizing percutaneous 
closure with two ProGlides or one ProStar, low vascular complication rates can be achieved. 
Careful patient selection, and screening with CT angiography or fluoroscopic angiography 
were used to identify patients at high risk of complications. Such complications occurred 
more often if the minimal artery diameter was smaller than the sheath external diameter, and 
in the presence of moderate or severe calcification. With the available alternative access 
routes (transaxillary, transapical, transaortic), such patients should not undergo transfemoral 
TAVI.  
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5. Long-term outcomes after transcatheter aortic valve replacement 
 
Since its introduction, the number of TAVI procedures was growing quickly world-wide. In 
2012, it was estimated that in third-world countries, 20-50% of patients with severe aortic 
stenosis now undergo TAVI. Despite the growing popularity of TAVI, previous reports have 
focused on short- and mid-term outcomes, while little was known about longer-term outcomes. 
A few reports have investigated outcome up to 3 years
31, 54
. From these reports, it was known 
that with current patient selection, median survival after TAVI was about 3 years. Accelerated 
in-vitro testing showed that valves may last up to 15 years. In the early series, the high 
mortality rate was unlikely due to valve deterioration, but more likely due to the types of 
patients undergoing TAVI. Another important issue was and still is the occurrence of strokes. 
In the PARTNER trial, TAVI has been associated with higher rates of strokes and transient 
ischemic attacks than surgery, although the combined endpoint of strokes and death was non-
significantly lower with TAVI compared to surgical AVR
7
. By analyzing long-term outcome, 
we also looked at the timing and type of strokes. We aimed to answer the following questions: 
 Do transcatheter aortic valves last 5 years or are there signs of structural valve 
degeneration? 
 Are there factors that predict long-term survival? 
 What is the long-term stroke rate? 
We analyzed 5 year outcome of the initial 111 patients undergoing TAVI at St. Paul’s 
Hospital, Vancouver, British Columbia from January 2005 to March 2007
55
. Patients with 
unsuccessful valve implantation or who died within 30 days were excluded from the analysis, 
leaving 88 patients who were assessed. Median survival time after TAVI was 3.4 years (95% 
CI 2.5, 4.4 years) and survival rates at 1-5 years were 83%, 74%, 53%, 42%, and 35%, 
respectively. Median survival time for patients with and without COPD was 2.3 and 3.9 years, 
respectively. Median survival time for patients with ≥ moderate PAR and mild/trivial/no PAR 
was 1.7 and 3.4 years. Mean aortic valve gradient decreased from 46 to 10 mmHg post TAVI, 
and was 11.8 mmHg after five years (p = 0.06 for post-TAVI trend). Mean aortic valve area 
increased from 0.62 to 1.67 cm2 post TAVI, and was 1.4 cm2 at five years (p<0.01 for post-
TAVI trend). 
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Figure 13. Mean gradients and aortic valve area remained stable with only marginal increase in gradient and mild 
decrease in valve area over time. (Toggweiler et al., J Am Coll Cardiol 2012;61:413-419) 
 
Up to 4 years, no patient had signs of structural valve deterioration, but at 5 years, 3 patients 
had moderate prosthetic valve dysfunction (moderate transvalvular regurgitation in one, 
moderate stenosis in one (aortic valve area 1.2 cm
2
, mean gradient 26 mmHg), and moderate 
mixed disease in one (aortic valve area 1.1 cm
2
, mean gradient 23 mmHg). However, no 
patient developed severe stenosis or severe regurgitation and no patient required re-operation. 
During the observation period, a total of 6 ischemic and 4 hemorrhagic major or fatal strokes 
occurred. Cumulative major ischemic stroke rate at 1-5 years was 3.6%, 5.2%, 7.3%, 7.3% 
and 9.7%, respectively, and 3/6 (50%) of ischemic strokes were fatal. Cumulative major 
hemorrhagic stroke rate at 1-5 years was 2.8%, 4.4%, 4.4%, 7.3%, and 7.3%, respectively, 
and 2/4 (50%) of hemorrhagic strokes were fatal.  
To put these findings in perspective, it is important to remember that these patients 
represented the first in-human experience with transfemoral and transapical TAVI in truly 
inoperable patients explaining the relatively poor long-term survival. However, 
hemodynamics were excellent and signs of moderate prosthetic valve failure were observed in 
only 3.4% of patients after 5 years.  
Cumulative ischemic stroke rate at 5 years was 9.7%, indicating an annual risk of ischemic 
strokes of about 2%. At the same time, cumulative major hemorrhagic stroke rate at 5 years 
was 7.3%. Of note, atrial fibrillation was present in 60% of these events indicating that atrial 
fibrillation may cause ischemic strokes (thromboembolism) and hemorrhagic strokes 
(bleeding due to antithrombotic therapy).  
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Stroke type Days post TAVI Risk factors Antiplatelet regimen Outcome 
Ischemic 2 Atrial fibrillation Aspirin, clopidogrel Patient survived 
Ischemic 54 None Aspirin, clopidogrel Patient died 
Ischemic 119 Atrial fibrillation Warfarin Patient died. 
Ischemic 637 None Aspirin Patient survived 
Ischemic 902 Carotid stenosis Aspirin Patient died 
Ischemic 1674 Atrial fibrillation Aspirin, clopidogrel Patient survived 
Hemorrhagic 203 Atrial fibrillation Warfarin, aspirin Patient died 
Hemorrhagic 211 Atrial fibrillation Warfarin Patient died 
Hemorrhagic 608 Atrial fibrillation Warfarin Patient survived 
Hemorrhagic 1405 None Aspirin, clopidogrel Patient survived 
Table 1.  Ischemic and hemorrhagic strokes up to 5 years post TAVI. (Toggweiler et al., J Am Coll Cardiol 2012;61:413-419) 
 
Based on our results, we were confident that transcatheter valves will last longer than 5 years 
and that patients with a longer life-expectancy will have long-term benefits from a durable 
valve. 
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6. Perspective 
 
Further refinement of the procedure and current developments  focus on minimizing vascular 
complications, reducing the risk for cerebrovascular accidents, improving paravalvular sealing, 
and facilitating accurate prosthesis implantation. Some of these issues may be addressed by 
next-generation valves that currently undergo early clinical evaluation. Most of these valves 
are constructed of self-expanding nitinol which offers the potential for recapture, 
repositioning, and removal, if required
56
.  
 
Figure 14. Next generation transcatheter heart valves. A: S3 (Edwards Lifesciences),B: Lotus Valve (Boston Scientific), C: 
Direct Flow (Direct Flow Medical), D: HLT System (Heart Leaflet Technologies),  E: Portico (St. Jude Medical), F: Centera 
(Edwards Lifesciences), G: Engager (Medtronic), H: JenaValve (JenaValve Technology), I: Accurate (Symetis), J: Inovare 
(Braile Biomedica). 
 
The S3 valve (Edwards Lifesciences, Irvine, USA) has a delivery system that is inserted 
through a 14 F expandable sheath which facilitates a fully percutaneous implantation in a 
broader range of patients. Furthermore, the valve has a parachute-like outer polyethylene 
terephthalate (PET) skirt that enhances paravalvular sealing
57
. 
Unlike other valves, the Direct Flow aortic valve (Direct Flow Medical, Santa Rosa, USA) is 
not based on a metallic stent frame technology. To deploy the valve, the lower ventricular and 
the upper aortic rings are inflated with 50%/50% saline/contrast. If required, repositioning can 
be performed after partial deflation, or the valve can be removed completely and exchanged 
for a valve of a different size. When correct position is achieved, the saline/contrast mix is 
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exchanged with a polymer which is firmly gelled within 90 minutes and fully cured within 24 
hours
58
. 
The Portico valve (St. Jude Medical Inc., St. Paul, USA), is a self-expanding valve very 
similar to a CoreValve. However, the Portico valve allows partial or complete recapture 
enabling the valve to be repositioned or removed. Only the 23 mm device is currently 
available
59
. 
The Centera valve (Edwards Lifesciences, Irvine, USA) is a relatively short self-expanding 
valve that does not extend into the ascending aorta for self-alignment or anchoring. The 
inflow is non-tubular flared, with a narrower annular segment and a larger diameter outflow. 
The idea behind this shape is to facilitate self-seating in the aortic annulus and reduce 
paravalvular regurgitation. The Centera valve can be deployed and if necessary recaptured 
using a single hand operated motorized delivery system
60
. 
The self-expanding Acurate valve (Symetis, Ecublens, Switzerland) has three stabilization 
arms meant to stabilize the valve in the ascending aorta. The valve has an upper crown that 
provides tactile feedback during positioning. Similar to a ‘hook concept’, optimal valve 
position is achieved by applying slight tension on the delivery system and thereby on the 
upper crown
61
. 
With improved equipment, and more experience, there is no doubt that rates of mortality, 
paravalvular regurgitation, strokes, and vascular complications will decrease. Compared to 
open heart surgery, TAVI is less invasive, allows earlier patient ambulation, and requires a 
shorter recovery and rehabilitation period. There is no doubt that the indication for TAVI will 
be extended and that TAVI will be applied in a broader spectrum of patients with severe 
aortic stenosis or regurgitation. 
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